Newsletter | November 7, 2026

11.07.26 -- Clinical Supply Leader Best Of October

OCTOBER'S BEST FEATURED EDITORIAL

Policy Is Redefining Clinical Trials. Clinical Supply Must Respond.

Clinical trial policy is shifting research closer to patients, creating new demands for forecasting, distribution, inventory, accountability, cold chain, and cross-functional planning.

The End Of Just-In-Time? Why Clinical Trial Supply Chains Are Rethinking Inventory Strategy

Clinical trials are too unpredictable for inventory strategies built on fixed assumptions. Learn why agility, visibility and smarter buffers are becoming essential to supply planning.

Clinical Trial Supply In The EU And U.K.: A Regulatory Guide

EU and U.K. clinical trial rules are evolving separately. Here’s what sponsors need to consider across QP release, labeling, importation, and supply continuity.

OCTOBER'S BEST INDUSTRY INSIGHTS

Program-Level Product Pooling With Demand-Led Clinical Supply

See how a global biopharmaceutical company was able to address inefficiencies and reduce waste within the clinical supply chain for a high-value therapy that faced strong demand but limited supply.

Navigating Supply Chains With UK And EU Qualified Persons

Gain essential insights into QP roles, regulatory updates, and best practices for ensuring compliance, supply continuity, and safe handling of cold and frozen pharmaceutical products across the UK and EU.

OCTOBER'S BEST SOLUTIONS

Flexible And Customized Order Solutions For Clinical Ancillary Management

Understanding Options In Direct-To-Patient Clinical Supply